» Articles » PMID: 37468791

Spastic Paraplegia Type 76 Due to Novel CAPN1 Mutations: Three Case Reports with Literature Review

Overview
Journal Neurogenetics
Specialty Neurology
Date 2023 Jul 19
PMID 37468791
Authors
Affiliations
Soon will be listed here.
Abstract

Spastic paraplegia type 76 (SPG76) is a subtype of hereditary spastic paraplegia (HSP) caused by calpain-1 (CAPN1) mutations. Our study described the phenotypic and genetic characteristics of three families with spastic ataxia due to various CAPN1 mutations and further explored the pathogenesis of the two novel mutations. The three patients were 48, 39, and 48 years old, respectively. Patients 1 and 3 were from consanguineous families, while patient 2 was sporadic. Physical examination showed hypertonia, hyperreflexia, and Babinski signs in the lower limbs. Patients 2 and 3 additionally had dysarthria and depression. CAPN1 mutations were identified by whole-exome sequencing, followed by Sanger sequencing and co-segregation analysis within the family. Functional examination of the newly identified mutations was further explored. Two homozygous mutations were detected in patient 1 (c.213dupG, p.D72Gfs*95) and patient 3 (c.1729+1G>A) with HSP, respectively. Patient 2 had compound heterozygous mutations c.853C>T (p.R285X) and c.1324G>A (p.G442S). Western blotting revealed the p.D72Gfs*95 with a smaller molecular weight than WT and p.G442S. In vitro, the wild-type calpain-1 is mostly located in the cytoplasm and colocalized with tubulin by immunostaining. However, p.D72Gfs*95 and p.G442S abnormally formed intracellular aggregation, with little colocalization with tubulin. In this study, we identified three cases with SPG76, due to four various CAPN1 mutations, presenting lower limb spasticity and ataxia, with or without bulbar involvement and emotional disorder. Among these, c.213dupG and c.1324G>A are first identified in this paper. The genotype-phenotype correlation of the SPG76 cases reported worldwide was further summarized.

References
1.
Ohno S, Minoshima S, Kudoh J, Fukuyama R, Shimizu Y, Shimizu N . Four genes for the calpain family locate on four distinct human chromosomes. Cytogenet Cell Genet. 1990; 53(4):225-9. DOI: 10.1159/000132937. View

2.
Baudry M . Calpain-1 and Calpain-2 in the Brain: Dr. Jekill and Mr Hyde?. Curr Neuropharmacol. 2019; 17(9):823-829. PMC: 7052842. DOI: 10.2174/1570159X17666190228112451. View

3.
Baudry M, Bi X . Calpain-1 and Calpain-2: The Yin and Yang of Synaptic Plasticity and Neurodegeneration. Trends Neurosci. 2016; 39(4):235-245. PMC: 4818674. DOI: 10.1016/j.tins.2016.01.007. View

4.
Moghadam S, Azami Tameh A, Vahidinia Z, Atlasi M, Hassani Bafrani H, Naderian H . Neuroprotective Effects of Oxytocin Hormone after an Experimental Stroke Model and the Possible Role of Calpain-1. J Stroke Cerebrovasc Dis. 2017; 27(3):724-732. DOI: 10.1016/j.jstrokecerebrovasdis.2017.10.020. View

5.
Gan-Or Z, Bouslam N, Birouk N, Lissouba A, Chambers D, Veriepe J . Mutations in CAPN1 Cause Autosomal-Recessive Hereditary Spastic Paraplegia. Am J Hum Genet. 2016; 98(6):1271. PMC: 4908182. DOI: 10.1016/j.ajhg.2016.05.009. View